Reporting of tumor lysis syndrome with targeted therapy for hepatic cancer in the FDA adverse events reporting system
BACKGROUND: Hepatic cancer is a common cancer in clinical practice. Current drug therapies for this condition include targeted therapy, chemotherapy, and immunotherapy. Tumor lysis syndrome (TLS) is the most serious complication of oncology treatment. According to the literature, several cases reported TLS occurred with targeted therapies for hepatic cancer.
METHODS: Reporting odds ratio and information component were used to measure the disproportionate signals for TLS associated with targeted therapies, using data from the FDA's Adverse Event Reporting System (FAERS). A stepwise sensitivity analysis was conducted to test the robustness of signals. Time-to-onset analysis was used to describe the latency of TLS events associated with targeted therapies. The Bradford Hill criteria were used to perform a global assessment of the evidence.
RESULTS: Sorafenib, lenvatinib, cabozantinib, and bevacizumab showed higher disproportionate signals for TLS than chemotherapy. The median number of days to TLS occurrence after drug therapy was 5.5, 6.5, and 6.5 days for sorafenib, lenvatinib, and bevacizumab, respectively.
CONCLUSIONS: There is a significant association between tumor lysis syndrome and targeted therapies for hepatic carcinoma, with particularly strong signals for sorafenib and lenvatinib. Clinicians should be aware of the potential for tumor lysis syndrome in targeted therapies for hepatic carcinoma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Expert opinion on drug safety - (2024) vom: 30. Jan., Seite 1-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Ling [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
FAERS |
|---|
| Anmerkungen: |
Date Revised 02.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/14740338.2024.2312147 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367793172 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367793172 | ||
| 003 | DE-627 | ||
| 005 | 20240202232207.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240130s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14740338.2024.2312147 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1278.xml |
| 035 | |a (DE-627)NLM367793172 | ||
| 035 | |a (NLM)38288971 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Ling |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Reporting of tumor lysis syndrome with targeted therapy for hepatic cancer in the FDA adverse events reporting system |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a BACKGROUND: Hepatic cancer is a common cancer in clinical practice. Current drug therapies for this condition include targeted therapy, chemotherapy, and immunotherapy. Tumor lysis syndrome (TLS) is the most serious complication of oncology treatment. According to the literature, several cases reported TLS occurred with targeted therapies for hepatic cancer | ||
| 520 | |a METHODS: Reporting odds ratio and information component were used to measure the disproportionate signals for TLS associated with targeted therapies, using data from the FDA's Adverse Event Reporting System (FAERS). A stepwise sensitivity analysis was conducted to test the robustness of signals. Time-to-onset analysis was used to describe the latency of TLS events associated with targeted therapies. The Bradford Hill criteria were used to perform a global assessment of the evidence | ||
| 520 | |a RESULTS: Sorafenib, lenvatinib, cabozantinib, and bevacizumab showed higher disproportionate signals for TLS than chemotherapy. The median number of days to TLS occurrence after drug therapy was 5.5, 6.5, and 6.5 days for sorafenib, lenvatinib, and bevacizumab, respectively | ||
| 520 | |a CONCLUSIONS: There is a significant association between tumor lysis syndrome and targeted therapies for hepatic carcinoma, with particularly strong signals for sorafenib and lenvatinib. Clinicians should be aware of the potential for tumor lysis syndrome in targeted therapies for hepatic carcinoma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a FAERS | |
| 650 | 4 | |a Pharmacovigilance | |
| 650 | 4 | |a hepatic cancer | |
| 650 | 4 | |a targeted therapy | |
| 650 | 4 | |a tumor lysis syndrome | |
| 700 | 1 | |a Zhang, Chengyi |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Huihui |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Huan |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Rong |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Mingxuan |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Pan |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Zhuzhu |e verfasserin |4 aut | |
| 700 | 1 | |a Gong, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Miao |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Zhichao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug safety |d 2002 |g (2024) vom: 30. Jan., Seite 1-7 |w (DE-627)NLM126588422 |x 1744-764X |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:30 |g month:01 |g pages:1-7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14740338.2024.2312147 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 30 |c 01 |h 1-7 | ||